Hemosiderosis - 22 Studies Found
| Completed |
: Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox : Transfusional Hemosiderosis : 2011-07-12 : Drug: deferasirox Other Name: ICL670 |
| Not yet recruiting |
: Efficacy of Bone Marrow Mesenchymal Stem Cell in Pulmonary Hemosiderosis : Idiopathic Pulmonary Hemosiderosis : 2016-12-03 : Biological: Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis |
| Completed |
: Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis :
: 2008-02-27 : Drug: Deferasirox (ICL670) The recommended initial daily dose of Deferasirox is 20 mg/kg body weight. |
| Completed |
: A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis :
: 2005-09-12 : Drug: deferasirox |
| Completed |
: Pharmacogenetic Study in Patients Received Iron Chelating Agent : Hemosiderosis : 2012-06-12 |
| Completed |
: Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food : Transfusional Hemosiderosis : 2009-02-16 : Drug: deferasirox: deferasirox 20mg/kg/day unless on a higher dose at time of study entry. Crushed or di |
| Completed |
: Safety, Tolerability, and Efficacy of Deferasirox in MDS :
: 2007-05-03 : Drug: Deferasirox |
| Completed |
: Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) :
: 2011-08-17 : Device: Non-contrast MRI Non-contrast MRI will be performed on each subject, at both 1.5T and 3.0T. Diff |
| Completed |
: Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload :
: |